Compare MPU & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPU | JSPR |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | 22 |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 14.9M |
| IPO Year | 2023 | N/A |
| Metric | MPU | JSPR |
|---|---|---|
| Price | $0.25 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 213.0K | ★ 732.4K |
| Earning Date | 04-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.32 |
| 52 Week High | $4.44 | $3.52 |
| Indicator | MPU | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 66.95 |
| Support Level | $0.21 | $0.62 |
| Resistance Level | $0.32 | $1.02 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 20.53 | 93.21 |
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.